# Vanderbilt CTU SARS-CoV-2 Supplement

> **NIH NIH UM1** · VANDERBILT UNIVERSITY MEDICAL CENTER · 2020 · $558,406

## Abstract

Project Summary
Coronavirus disease 2019 (COVID-19) pandemic caused by Severe Acute Respiratory Syndrome coronavirus
2 (SARS-CoV-2) required a rapid, coordinated response. The pandemic has interfered with many other important
endeavors, including NIH-sponsored non-COVID HIV clinical trials. We need robust plans to implement
measures to expand SARS-CoV-2, allowing research units to resume studies being conducted on HIV, while
maintaining the safety and well-being of participants and staff. To this end, we have developed strategies relying
on a combination of testing for active disease, evaluating seroprevalence, and conducting operations in ways
that enforce social distancing and utilization of personal protective equipment (PPE). This project is being
implemented at the Vanderbilt Therapeutics Clinical Research Site (VT-CRS), and the Washington University
Prevention & Therapeutics (WPT) CRS. This strategy will comprise two aims that involve research participants,
their household contacts, and staff: Aim 1) To utilize resources obtained through this administrative supplement
to expand SARS-CoV-2 testing within the regions of our Clinical Research Sites; and Aim 2) To utilize resources
obtained through this administrative supplement to more quickly and fully resume on-site research activities at
our Clinical Research Sites. Among the activities to be implemented are universal testing of study participants
for infection by SARS-CoV-2 PCR prior to study visits, either by staff during parking lot drive-through visits or self-
collected remotely by study participants. At one CRS, testing will also be offered to adult household contacts of
study participants. There will be active screening for symptoms of COVID-19. There will be SARS-CoV-2 antibody
testing at the beginning and end of the project period, of staff and/or study participants. This project will
substantially expanding SARS-CoV-2 testing, and expedite the opening of our NIAID-funded CRSs. In addition, the
experience and information gained during this project will inform future strategies to further expand testing and
facilitate clinical trials operations.

## Key facts

- **NIH application ID:** 10166023
- **Project number:** 3UM1AI069439-15S1
- **Recipient organization:** VANDERBILT UNIVERSITY MEDICAL CENTER
- **Principal Investigator:** David W Haas
- **Activity code:** UM1 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $558,406
- **Award type:** 3
- **Project period:** 2020-06-02 → 2020-11-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10166023

## Citation

> US National Institutes of Health, RePORTER application 10166023, Vanderbilt CTU SARS-CoV-2 Supplement (3UM1AI069439-15S1). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10166023. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*